This study is designed to evaluated implementation of PrEP treatment as a part of the general HIV preventive program in Norway. The target groups are mainly MSM and transgender persons at high risk of HIV infection, as well as other subjects at risk of HIV infection due to their sexual practices.
Objectives include assessment of the following:
1. Assess the impact of PrEP on the sexual and psychological health of PrEP users Incidence of sexually transmitted infections (STIs) in PrEP users compared to those not taking PrEP
2. Assessment of drug compliance
3. Incidence of HIV seroconversion despite PrEP
4. Frequency and development of drug resistance in subjects who HIV-seroconvert (if any)
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Male, female or transgender persons aged ≥ 18 years who are offered or have started PrEP in routine clinical practice, and 2, 3, 4, 5, 6 or 7 (below).
2. Men who have sex with men (MSM) and transgender persons;
1. who have had unprotected anal sex with two or more partners during the last six months and/or
2. who have had bacterial sexually transmittable infection(s) during the last twelve months and/or
3. who have used post-exposure prophylaxis(PEP) during the last twelve months and/or
4. who use recreational drugs when having sex
3. Indication for PrEP is present according to the assessment of the health care provider
4. Men and women who are at high risk of HIV according to their sexual practices
5. HIV-negative partner of a HIV-positive person not yet virologically suppressed by antiretroviral therapy (ART)
6. Sex workers with inconsistent condom use
7. Persons with inconsistent condom use with sexual partners in / from countries with a high prevalence of HIV (COHP)
You may not be if
1. HIV positive subjects
2. Subjects who cannot take Emtricitabine/tenofovir disoproxil combination tablet (FTC/TDF) due to contraindications
Clareo Health | Evaluation of Implementation of Pre-exposure Prophylaxis (PrEP) in Norway
